Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC)

Doktorovová, Slavomíra; Araújo, Joana; García, Montse; Rakovský, Erik; Souto, Eliana B.

doi:10.1016/j.colsurfb.2009.09.033

Cited by 129 publications

(57 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The melting point of lipid nanoparticles (SLN and NLC) was lower than the bulk lipid (CP) and the depression became more pronounced with increasing the amount of CA in NLC (Figure 4). This is in agreement with the previous research (Doktorovovaa et al, 2010). According to the Gibbs-Thomson equation (Jackson and McKenna, 1990) for a spherical solid particle of diameter x, melting point depression is inversely proportional to the size of the nanoparticle…”

Section: Differential Scanning Calorimetrysupporting

confidence: 93%

Development of nanostructured lipid carriers for controlled delivery of mefenamic acid

Khurana

Bedi

Jain

2012

IJBNN

View full text Add to dashboard Cite

This study was aimed to develop nanostructured lipid carriers (NLC) for the possible delivery of mefenamic acid. This study describes the effect of liquid lipid concentration on the characteristics of NLC such as particle size, polydispersity index, zeta potential, drug entrapment efficiency, and occlusivity index. Transmission electron microscopy revealed nearly spherical shape NLC with negligible effect of liquid lipid content on the particle morphology. The differential scanning calorimetry demonstrated a depression in the melting point and crystallinity index of the NLC with an increase in the amount of liquid lipid. The in vitro drug release studies demonstrated that solid lipid nanoparticle (0% oil), and NLC possessed a biphasic release pattern characterised by a rapid initial release followed by a sustained release, in comparison to nanoemulsions (100% oil) of which a nearly constant release was observed. Compared to NE and SLN, the excellent physical stability of NLC against drug leakage was seen.

show abstract

Section: Differential Scanning Calorimetrysupporting

confidence: 93%

Development of nanostructured lipid carriers for controlled delivery of mefenamic acid

Khurana

Bedi

Jain

2012

IJBNN

View full text Add to dashboard Cite

show abstract

“…Doktorovová et al [94] developed PEGylated-based NLC through the blend between Precirol (solid lipid) and a PEGylated liquid lipid (Labrasol) for the sustained delivery of fluticasone propionate in dermatology. The nanoparticles showed excellent encapsulation efficiency (95%) and physicochemical stability (60 days), stored at room temperature.…”

Section: Innovative Hybrid Lipid Nanoparticles: Solid Lipid Nanopartimentioning

confidence: 99%

“…In vivo pharmacokinetics studies in rats demonstrated higher bioavailability of hybrid artesunateloaded lipospheres when compared to the commercial tablet for malaria treatment [104]. Different in vivo studies were described for SLN-and NLC-based hybrid systems for topical and parenteral applications, using mice, rat, and rabbit, as well as in human clinical trial, which demonstrated the effectiveness, nontoxicity, and bioavailability of these biodevices compared to their respective traditional DDS or free drug [86,88,94,96].…”

Section: In Vivo Performance Of Biohybrid Polymer-based Hybrid Ddsmentioning

confidence: 99%

Advances in Hybrid Polymer-Based Materials for Sustained Drug Release

Ribeiro

Alcántara

Silva

et al. 2017

International Journal of Polymer Science

View full text Add to dashboard Cite

The use of biomaterials composed of organic pristine components has been successfully described in several purposes, such as tissue engineering and drug delivery. Drug delivery systems (DDS) have shown several advantages over traditional drug therapy, such as greater therapeutic efficacy, prolonged delivery profile, and reduced drug toxicity, as evidenced by in vitro and in vivo studies as well as clinical trials. Despite that, there is no perfect delivery carrier, and issues such as undesirable viscosity and physicochemical stability or inability to efficiently encapsulate hydrophilic/hydrophobic molecules still persist, limiting DDS applications. To overcome that, biohybrid systems, originating from the synergistic assembly of polymers and other organic materials such as proteins and lipids, have recently been described, yielding molecularly planned biohybrid systems that are able to optimize structures to easily interact with the targets. This work revised the biohybrid DDS clarifying their advantages, limitations, and future perspectives in an attempt to contribute to further research of innovative and safe biohybrid polymer-based system as biomaterials for the sustained release of active molecules.

show abstract

“…Additionally, NLC can realize passive targeting by altering particle size and achieve active targeting features by modification using proper materials (Jia et al, 2010b;Zhao et al, 2011). They also can be PEGylated to enhance long circulation (Doktorovová et al, 2010;Jia et al, 2012). Hence, NLC appear to be an ideal formulation for the efficient delivery of Amoitone B.…”

Section: Introductionmentioning

confidence: 99%

Design and characterization of Amoitone B-loaded nanostructured lipid carriers for controlled drug release

et al. 2013

View full text Add to dashboard Cite

Amoitone B, a novel compound chemically synthesized as the analogue of cytosporone B, has been proved to own superior affinity with Nur77 than its parent compound and exhibit notable anticancer activity. However, its application is seriously restricted due to the water-insolubility and short biological half-time. The aim of this study was to construct an effective delivery system for Amoitone B to realize sustained release, thus prolong drug circulation time in body and improve the bioavailability. Nanostructured lipid carriers (NLC) act as a new type of colloidal drug delivery system, which offer the advantages of improved drug loading and sustained release. Amoitone B-loaded NLC (AmB-NLC) containing glyceryl monostearate (GMS) and various amounts of medium chain triglycerides (MCT) were successfully prepared by emulsion-evaporation and low temperature-solidification technology with a particle size of about 200 nm and a zeta potential value of about À20 mV. The results of X-ray diffraction and DSC analysis showed amorphous crystalline state of Amoitone B in NLC. Furthermore, the drug entrapment efficacy (EE) was improved compared with solid lipid nanoparticles (SLN). The EE range was from 71.1% to 84.7%, enhanced with the increase of liquid lipid. In vitro drug release studies revealed biphasic drug release patterns with burst release initially and prolonged release afterwards and the release was accelerated with augment of liquid lipid. These results demonstrated that AmB-NLC could be a promising delivery system to control drug release and improve loading capacity, thus prolong drug action time in body and enhance the bioavailability.

show abstract

Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC)

Cited by 129 publications

References 24 publications

Development of nanostructured lipid carriers for controlled delivery of mefenamic acid

Development of nanostructured lipid carriers for controlled delivery of mefenamic acid

Advances in Hybrid Polymer-Based Materials for Sustained Drug Release

Design and characterization of Amoitone B-loaded nanostructured lipid carriers for controlled drug release

Contact Info

Product

Resources

About